Aidan King, MBA, CFA

Aidan, qualified by training as a pharmacist from Trinity College Dublin, enjoys the challenge presented by investing in a rapidly changing life science market. Aidan started his industry career at Elan in pharmaceutical strategic marketing before moving to New York to work in Elan’s corporate venture capital group, where investments included Quadrant Healthcare (acquired by Elan, 2000), Atrix laboratories (acquired by QLT, 2004), Idun Pharmaceuticals (acquired by Pfizer, 2005) and Zealand Pharmaceuticals (IPO, 2010).
Aidan primarily focuses on US investments, marketing and fund raising and he currently sits on the boards of Xylocor Therapeutics and Corteria Pharmaceuticals. Previously, he was the firm’s representative on the boards of Syndesi Therapeutics (acquired by Abbvie, 2022), Civitas Therapeutics (acquired by Acorda, 2014), Chrono Therapeutics, Velicept Therapeutics and Palyon Medical